Compare ALEMBIC PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ELDER PHARMA ALEMBIC PHARMA/
ELDER PHARMA
 
P/E (TTM) x 15.3 -0.2 - View Chart
P/BV x 3.8 0.1 3,773.8% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 ALEMBIC PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ELDER PHARMA
Jun-14
ALEMBIC PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs664380 174.7%   
Low Rs412188 219.4%   
Sales per share (Unadj.) Rs208.7491.2 42.5%  
Earnings per share (Unadj.) Rs31.0-3.2 -974.3%  
Cash flow per share (Unadj.) Rs37.114.4 257.6%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.2376.5 38.3%  
Shares outstanding (eoy) m188.5220.54 917.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.60.6 446.0%   
Avg P/E ratio x17.4-89.3 -19.5%  
P/CF ratio (eoy) x14.519.7 73.6%  
Price / Book Value ratio x3.70.8 494.7%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,4615,833 1,739.3%   
No. of employees `000NANA-   
Total wages/salary Rs m7,4672,179 342.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m39,34710,089 390.0%  
Other income Rs m94257 36.6%   
Total revenues Rs m39,44110,346 381.2%   
Gross profit Rs m8,736-792 -1,103.1%  
Depreciation Rs m1,152361 318.9%   
Interest Rs m1842,756 6.7%   
Profit before tax Rs m7,493-3,653 -205.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m1,568125 1,252.5%   
Profit after tax Rs m5,844-65 -8,942.2%  
Gross profit margin %22.2-7.8 -282.9%  
Effective tax rate %20.9-3.4 -610.6%   
Net profit margin %14.9-0.6 -2,292.9%  
BALANCE SHEET DATA
Current assets Rs m19,5779,240 211.9%   
Current liabilities Rs m14,8969,998 149.0%   
Net working cap to sales %11.9-7.5 -158.4%  
Current ratio x1.30.9 142.2%  
Inventory Days Days9046 193.8%  
Debtors Days Days4560 75.7%  
Net fixed assets Rs m27,09710,124 267.7%   
Share capital Rs m377206 183.3%   
"Free" reserves Rs m26,8115,582 480.3%   
Net worth Rs m27,1887,734 351.6%   
Long term debt Rs m4,9934,889 102.1%   
Total assets Rs m47,77822,882 208.8%  
Interest coverage x41.7-0.3 -12,819.8%   
Debt to equity ratio x0.20.6 29.0%  
Sales to assets ratio x0.80.4 186.8%   
Return on assets %12.611.8 107.3%  
Return on equity %21.5-0.8 -2,543.5%  
Return on capital %23.622.3 105.8%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m19,453307 6,344.7%   
Fx outflow Rs m6,065125 4,840.2%   
Net fx Rs m13,388181 7,384.4%   
CASH FLOW
From Operations Rs m8,12011,754 69.1%  
From Investments Rs m-7,556-561 1,348.1%  
From Financial Activity Rs m590-6,762 -8.7%  
Net Cashflow Rs m1,1534,432 26.0%  

Share Holding

Indian Promoters % 74.1 39.6 187.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 16.8 54.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 36.1 38.5%  
Shareholders   49,328 16,479 299.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  FDC LTD.  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Nov 19, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS